Keyphrases
Antibody-drug Conjugate
100%
Cyclobutane Pyrimidine Dimers
65%
Human Epidermal Growth Factor Receptor 2 (HER2)
60%
Antitumor Activity
48%
Esophageal Adenocarcinoma
40%
Faroe Islands
40%
Photodynamic Therapy
32%
DNA Interstrand Crosslinks
31%
Pyrrolobenzodiazepine
29%
Tesirine
25%
Photoactive
25%
Therapeutic Potential
24%
Warhead
22%
Mechanism of Action
22%
Tumor
21%
HER2-positive
20%
Seroprevalence
20%
Phototherapy
20%
Surgical Resection
20%
Resection Guidance
20%
SARS-CoV-2 Antibodies
20%
Close Contact
20%
COVID-19 Patients
20%
Prostate Cancer
20%
Theranostic Agent
20%
Preclinical Development
20%
Clinical Pharmacology
20%
Mucin Glycoprotein
20%
Prostate-specific Antigen
20%
T-DM1
20%
Solid Tumors
20%
Persistent Organic Pollutants
20%
Core Program
20%
Metal-organic Materials
20%
Heavy Metals
20%
Arctic Monitoring
20%
Assessment Programs
20%
Monitoring Program
20%
Cytotoxicity
19%
Patient-derived Xenograft
18%
Resection
13%
High Efficiency
13%
Auristatin
13%
Pharmacokinetics
10%
NIR Dyes
10%
COVID-19
10%
Xenograft
9%
Dose Effect
9%
Humanized
9%
Cell Killing
9%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
65%
Dimer
65%
Antitumor Activity
60%
Antibody Drug Conjugate
60%
Esophageal Adenocarcinoma
40%
Photodynamic Therapy
32%
Tesirine
26%
Solid Malignant Neoplasm
26%
Cytotoxicity
21%
Prostate Specific Membrane Antigen
20%
Gamma Urogastrone
20%
Epidermal Growth Factor Receptor 2
20%
Prostate Cancer
20%
Glycoprotein
20%
Mucin
20%
Preclinical Pharmacology
20%
Malignant Neoplasm
17%
Pharmacokinetics
14%
Cancer Model
13%
Immunoglobulin F(ab) Fragment
13%
Photosensitizer
10%
Recurrent Disease
10%
Mouse Model
10%
Trastuzumab
10%
Clinical Trial
9%
Flow Cytometry
8%
Cytotoxin
6%
Chemotherapy
6%
Ovary Cancer
6%
Hematologic Malignancy
6%
Cancer Growth
6%
Olaparib
6%
Tolerability
6%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
6%
Lung Cancer
6%
Tyrosine Kinase Receptor
6%
Lysine
6%
Early Cancer
6%
Cancer Infiltration
6%
Disulfide
6%
Stomach Adenocarcinoma
6%
Multidrug Resistance
6%
Excision Repair Cross Complementing Protein 1
6%
Monomer
6%
Plasmid DNA
6%
Castration Resistant Prostate Cancer
5%
Medicine and Dentistry
Dimer
45%
Antibody-Drug Conjugate
40%
Antineoplastic Activity
36%
Cross-Link
36%
Tesirine
26%
Xenograft
25%
Solid Malignant Neoplasm
24%
Surgery
24%
Photochemotherapy
20%
Prostate Specific Membrane Antigen
20%
COVID-19
20%
Antibodies
20%
Seroprevalence
20%
Severe Acute Respiratory Syndrome Coronavirus 2
20%
Prostate Cancer
20%
Neoplasm
18%
In Vitro
16%
Cytotoxicity
13%
Cell Line
13%
Single Drug Dose
13%
Immunoglobulin F(ab) Fragment
10%
Internalization
9%
DNA Cross Linking
9%
Trastuzumab
8%
Household
8%
Cancer Cell Line
7%
Clinical Trial
6%
Tumor Xenograft
6%
Prostate Cancer Cell Line
5%
Castration Resistant Prostate Cancer
5%
Flow Cytometry
5%
Photosensitizer
5%
Recurrent Disease
5%
Early Intervention
5%
Disulfide
5%
Cancer Infiltration
5%
Lysine
5%
Therapeutic Agent
5%
Lymph Node
5%
Stomach Adenocarcinoma
5%
Cancer
5%